
News|Articles|January 1, 2002
Emerging uses of the new anticonvulsants: What's the state of the evidence? (PDF)
Like their older counterparts, the newer anticonvulsants gabapentin, lamotrigine, and topiramate show promise for treating various off-label psychiatric and neurologic disorders. This review examines the quality of current evidence for these new uses, identifies where gaps in the evidence lie, and discusses which emerging uses of individual agents appear most justified.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Who will pay for Trump program to have Medicare cover GLP-1s for obesity?
2
Parsing the sizable life expectancy gap for people with schizophrenia
3
Relmada Therapeutics appoints Max Kates to clinical advisory board to support NDV-01 phase 3 program for bladder cancer
4
Wearable patch could flag melanoma risk earlier than visual inspection
5




















































